Loading clinical trials...

A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

NCT04911751•KoBioLabs

View on ClinicalTrials.gov

Summary

The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female, aged 18 to 75 years (inclusive)
•Have a diagnosis of plaque type psoriasis for ≥ 6 months
•Must have chronic plaque type psoriasis of moderate severity
•All subjects must agree and commit to the use of a reliable contraceptive regimen.

Exclusion Criteria

•Current diagnosis of forms of psoriasis other than chronic plaque type only
•Drug-induced psoriasis
•Other inflammatory skin disease that may confound the evaluation of plaque psoriasis
•Failed 2 or more systemic treatments for plaque psoriasis
•Medicinal shampoos that contain tar and/or salicylic acid within 2 weeks prior to Baseline Visit

Locations (10)

Total Skin and Beauty Dermatology Center

Birmingham, Alabama, United States

Southern California Dermatology, Inc

Santa Ana, California, United States

Clinical Science Institute

Santa Monica, California, United States

Revival Research Institute

Doral, Florida, United States

Indago Research and Health Center

Hialeah, Florida, United States

Louisiana Dermatology Associates - Dermatology

Baton Rouge, Louisiana, United States

Premier Specialist

Kogarah, New South Wales, Australia

Westmead Hospital

Westmead, New South Wales, Australia

Veracity Clinical Trials Ltd

Woolloongabba, Queensland, Australia

Sinclair Dermatology

East Melbourne, Victoria, Australia

Key Dates

Start Date

November 8, 2021

Primary Completion Date

November 8, 2023

Completion Date

October 7, 2024

Last Updated

January 7, 2025

Enrollment

ACTUAL participants

Conditions

Psoriatic Plaque

Interventions

KBL697

DRUG

KBL697

DRUG

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

NCT04099979

PsoriasisPsoriasis Vulgaris+12 more

View study

UNKNOWN

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

NCT05144165

PsoriasisPsoriasis Palmaris+9 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

Inclusion Criteria

Exclusion Criteria

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis